Treatment for Spinal Amyotrophy is in Health Committee of the Romanian Senate’s attention

At the initiative of the Romanian Senate’s Health Comission’s members, on Tuesday, 27th of June 2017, the debate took place on the occasion of the approval of the first medicine for Muscular Spinal Amyotrophy.

The event preceded the Press Conference "Together for life - the chance for normalcy", which aimed to encourage communication between people affected by Muscular Spinal Amyotrophy, specialists and public health authorities.

Mr. Vlad Negulescu, from the National Agency for Medicines and Medical Equipment, said that the legislation necessary to bring the new treatment on the market exists, and Romania is interested in this treatment for all types of MSA and asked for a concrete price offer, from representatives of BIOGEN, the company that brings this medicine to the European market.

Mrs. Cristina Șiclovan, CNAS, mentioned that this is an innovative medicine, and MSA is not yet included in the program of rare diseases. Regarding the reimbursement of the related medical devices, CNAS will debate the proposals on this subject during September - October of this year.

During the event that preceded the Press Conference "Together for life - the chance for normalcy", held by MaxBet, Mrs. Jane Cooper, BIOGEN representative, said that the first European country where the medicine will be available is Germany, and the price at which it will enter the market is 90,000 euros / vial. Mrs. Jane Cooper asked the competent authorities for a list of requirements and information on the new medicine, which would help the company return in two to three weeks with a concrete price offer.